UNSPSC 51123116: Procainamide hydrochloride

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C13H21N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SI4064O0LX, chemically known as benzamide, p-amino-n-(2-(diethylamino)ethyl)-, hydrochloride but more generally known as procainamide hydrochloride, which bears US NIH Compound Identifier 66068. European Medicines Agency schedules Procainamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04045MIG.

UNSPSC 51123116 Procainamide hydrochloride is a Commodity code encompassing individual pharmaceutical products used in emergency medical care and institutional health settings. State and local governments procure this and related advanced life support medications for emergency response agencies, health systems, and institutional pharmacy programs. The work involves supplying finished pharmaceutical products with specified strength, dosage form, and National Drug Code compliance, managed through sealed competitive bidding or cooperative purchasing frameworks that require vendor certification of Good Manufacturing Practices, Drug Supply Chain Security Act compliance, and detailed product specifications including NDC codes, expiration-date warranties, and OSHA hazard documentation.

Recent opportunities under this code originate from city fire rescue services, state health departments, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for advanced life support medications (including epinephrine, adenosine, diltiazem, and labetalol) with a $40,000 estimated value and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; awards were to be made to one or multiple vendors based on price competitiveness (75 percent weight) and regulatory and operational compliance criteria. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a direct-to-manufacturer prescription fulfillment program, signaling exploratory procurement strategy development ahead of a formal RFP. Activity concentrates in Texas, Minnesota, and Florida, with multistate cooperative purchasing vehicles expanding reach across participating jurisdictions.